Allena Pharmaceuticals, Inc. Operating Income Growth

Operating Income Growth of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating Income Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Operating Income Growth for the quarter ending March 31, 2022 was -1.29% (a -5.15% decrease compared to previous quarter)
  • Year-over-year quarterly Operating Income Growth decreased by -98.81%
  • Annual Operating Income Growth for 2021 was -48.97% (a -249.76% decrease from previous year)
  • Annual Operating Income Growth for 2020 was 32.7% (a -197.55% decrease from previous year)
  • Annual Operating Income Growth for 2019 was -33.52% (a -52.04% decrease from previous year)
  • Twelve month Operating Income Growth ending March 31, 2022 was -33.24% (a -32.12% decrease compared to previous quarter)
  • Twelve month trailing Operating Income Growth increased by 200.27% year-over-year
Trailing Operating Income Growth for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-33.24% -48.97% -42.71% -11.07%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating Income Growth of Allena Pharmaceuticals, Inc.

Most recent Operating Income Growthof ALNA including historical data for past 10 years.

Interactive Chart of Operating Income Growth of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Operating Income Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 -1.29%
2021 -1.36% -57.0% -108.68% -51.65% -48.97%
2020 11.58% 40.64% 42.13% 34.91% 32.7%
2019 -15.47% -37.43% -39.34% -44.98% -33.52%
2018 -48.84% -122.49% -81.79% -43.87% -69.89%
2017 -7.69% 55.05% 44.99% 30.49% 13.38%
2016 7.14% -73.94%
2015 42.51%

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.